Molecular Partners AG (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.

The companies entered into an initial agreement in January 2024 to co-develop four programs.

Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.

Financial terms were not disclosed.

The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.